This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Furuta, Y. Articles by Shiraki, K. Search for Related Content PubMed PubMed Citation Articles by Furuta, Y. Articles by Shiraki, K.

In Vitro and In Vivo Activities of Anti-Influenza Virus Compound T-705

Research Laboratories, Toyama Chemical Co., Ltd., 2-4-1 Shimookui,¹ Department of Virology, Toyama Medical and Pharmaceutical University, 2630 Sugitani, Toyama, Japan²

Received 29 June 2001/ Returned for modification 10 September 2001/ Accepted 27 December 2001

T-705 (6-fluoro-3-hydroxy-2-pyrazinecarboxamide) has been found to have potent and selective inhibitory activity against influenza virus. In an in vitro plaque reduction assay, T-705 showed potent inhibitory activity against influenza A, B, and C viruses, with 50% inhibitory concentrations (IC₅₀s) of 0.013 to 0.48 µg/ml, while it showed no cytotoxicity at concentrations up to 1,000 µg/ml in Madin-Darby canine kidney cells. The selectivity index for influenza virus was more than 2,000. It was also active against a neuraminidase inhibitor-resistant virus and some amantadine-resistant viruses. T-705 showed weak activity against non-influenza virus RNA viruses, with the IC₅₀s being higher for non-influenza virus RNA viruses than for influenza virus, and it had no activity against DNA viruses. Orally administered T-705 at 100 mg/kg of body weight/day (four times a day) for 5 days significantly reduced the mean pulmonary virus yields and the rate of mortality in mice infected with influenza virus A/PR/8/34 (3 x 10² PFU). These results suggest that T-705 may be a compound that is useful and highly selective against influenza virus infections and that has a mode of action different from those of commercially available drugs, such as amantadine, rimantadine, and neuraminidase inhibitors.

This article has been cited by other articles:

• Gowen, B. B., Wong, M.-H., Jung, K.-H., Sanders, A. B., Mendenhall, M., Bailey, K. W., Furuta, Y., Sidwell, R. W. (2007). In Vitro and In Vivo Activities of T-705 against Arenavirus and Bunyavirus Infections. Antimicrob. Agents Chemother. 51: 3168-3176 [Abstract] [Full Text]  
• Julander, J. G., Furuta, Y., Shafer, K., Sidwell, R. W. (2007). Activity of T-1106 in a Hamster Model of Yellow Fever Virus Infection. Antimicrob. Agents Chemother. 51: 1962-1966 [Abstract] [Full Text]  
• Sidwell, R. W., Barnard, D. L., Day, C. W., Smee, D. F., Bailey, K. W., Wong, M.-H., Morrey, J. D., Furuta, Y. (2007). Efficacy of Orally Administered T-705 on Lethal Avian Influenza A (H5N1) Virus Infections in Mice. Antimicrob. Agents Chemother. 51: 845-851 [Abstract] [Full Text]  
• Furuta, Y., Takahashi, K., Kuno-Maekawa, M., Sangawa, H., Uehara, S., Kozaki, K., Nomura, N., Egawa, H., Shiraki, K. (2005). Mechanism of Action of T-705 against Influenza Virus. Antimicrob. Agents Chemother. 49: 981-986 [Abstract] [Full Text]  
• McSharry, J. J., McDonough, A. C., Olson, B. A., Drusano, G. L. (2004). Phenotypic Drug Susceptibility Assay for Influenza Virus Neuraminidase Inhibitors. CVI 11: 21-28 [Abstract] [Full Text]